Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas

Cancer Gene Therapy

Volumn 16, Issue 11, 2009, Pages 848-860

  Vardouli, L ^a   Lindqvist, C ^b   Vlahou, K ^a   Loskog, A S I ^b   Eliopoulos, A G ^a,c  

^a UNIVERSITY OF CRETE   (Greece)

^b UPPSALA UNIVERSITY   (Sweden)

^c INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Greece)

Author keywords

Adenovirus; Apoptosis; Carcinoma; CD154; CD40; Gene therapy

Indexed keywords

ADENOVIRUS VECTOR; CD40 LIGAND; CISPLATIN; FLUOROURACIL; MITOMYCIN C; RECOMBINANT ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CELL KILLING; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; GENE TRANSFER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CD40 LIGAND; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; FLOW CYTOMETRY; FLUOROURACIL; GENE THERAPY; HUMANS; IMMUNOBLOTTING; MICE; MICE, NUDE; MITOMYCIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE;

EID: 70350123858     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.31     Document Type: Article

References (48)

1. Noelle RJ. CD40 and its ligand in host defense. Immunity 1996; 4: 415-419.
2. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2-17.
3. Mackey MF, Gunn JR, Maliszewski C, Kikutani H, Noelle RJ, Barth RJ. Dendritic cells require maturation via CD40 to generate protective anti-tumour immunity. J Immunol 1998; 161: 2094-2098.
4. Kikuchi T, Crystal RG. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum Gene Ther 1999; 10: 1375-1387.
5. Sun Y, Peng D, Lecanda J, Schmitz V, Barajas M, Qian C et al. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Gene Ther 2000; 7: 1467-1476.
6. Loskog A, Dzojic H, Vikman S, Ninalga C, Essand M, Korsgren O et al. Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor microenvironment. J Immunol 2004; 172: 7200-7205.
7. Noguchi M, Imaizumi K, Kawabe T, Wakayama H, Horio Y, Sekido Y et al. Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer. Cancer Gene Ther 2001; 8: 421-429.
8. Loskog A, Bjorkland A, Brown MP, Korsgren O, Mal-mstrom PU, Totterman TH. Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. J Urol 2001; 166: 1093-1097.
9. Loskog AS, Fransson ME, Totterman TT. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Clin Cancer Res 2005; 11: 8816-8821.
10. Hill SC, Youde SJ, Man S, Teale GR, Baxendale AJ, Hislop A et al. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol 2005; 174: 41-50.
11. Sabel MS, Yamada M, Kawaguchi Y, Chen FA, Takita H, Bankert RB. CD40 expression on human lung cancer correlates with metastatic spread. Cancer Immunol Immun-other 2000; 49: 101-108.
12. Eliopoulos AG, Dawson CW, Mosialos G, Floettmann JE, Rowe M, Armitage RJ et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 1996; 13: 2243-2254.
13. Tong AW, Papayoti MH, Netto G, Armstrong DT, Ordonez G, Lawson JM et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 2001; 7: 691-703.
14. Ghamande S, Hylander BL, Oflazoglu E, Lele S, Fanslow W, Repasky EA. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res 2001; 61: 7556-7562.
15. Hirano A, Longo DL, Taub DD, Ferris DK, Young LS, Eliopoulos AG et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 1999; 93: 2999-3007.
16. Eliopoulos AG, Davies C, Knox PG, Gallagher NJ, Afford SC, Adams DH et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 2000; 20: 5503-5515.
17. Grell M, Zimmermann G, Gottfried E, Chen CM, Grunwald U, Huang DC et al. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J 1999; 18: 3034-3043.
18. Hess S, Engelmann H. A novel function of CD40: induction of cell death in transformed cells. J Exp Med 1996; 183: 159-167.
19. Shaw NJ, Georgopoulos NT, Southgate J, Trejdosiewicz LK. Effects of loss of p53 and p16 function on life span and survival of human urothelial cells. Int J Cancer 2005; 116: 634-639.
20. Davies CC, Bem D, Young LS, Eliopoulos AG. NF-kappaB overrides the apoptotic program of TNF receptor 1 but not CD40 in carcinoma cells. Cell Signal 2005; 17: 729-738.
21. Eliopoulos AG, Young LS. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004; 4: 360-367.
22. Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 2003; 10: 1-13.
23. Dallman C, Johnson PW, Packham G. Differential regulation of cell survival by CD40. Apoptosis 2003; 8: 45-53.
24. Vonderheide RH, Dutcher JP, Anderson JE, Eckhardt SG, Stephans KF, Razvillas B et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 2001; 19: 3280-3287.
25. O'Toole CM, Povey S, Hepburn P, Franks LM. Identity of some human bladder cancer cell lines. Nature 1983; 301: 429-430.
26. Marshall CJ, Franks LM, Carbonell AW. Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas. J Natl Cancer Inst 1977; 58: 1743-1751.
27. Dzojic H, Loskog A, Totterman TH, Essand M. Adeno-virus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model. Prostate 2006; 66: 831-838.
28. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene 1995; 11: 1217-1228.
29. Slinker BK. The statistics of synergism. J Mol Cell Cardiol 1998; 30: 723-731.
30. Georgopoulos NT, Steele LP, Thomson MJ, Selby PJ, Southgate J, Trejdosiewicz LK. A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Differ 2006; 13: 1789-1801.
31. Kim CY, Jeong M, Mushiake H, Kim BM, Kim WB, Ko JP et al. Cancer gene therapy using a novel secretable trimeric TRAIL. Gene Ther 2006; 13: 330-338.
32. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997; 186: 2045-2050.
33. Schneider P, Holler N, Bodmer J-L, Hahne M, Frei K, Fontana A et al. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with down-regulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187: 1205-1213.
34. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nature Med 1998; 4: 31-36.
35. Matthies KM, Newman JL, Hodzic A, Wingett DG. Differential regulation of soluble and membrane CD40L proteins in T cells. Cell Immunol 2006; 241: 47-58.
36. Knox PG, Milner AE, Green NK, Eliopoulos AG, Young LS. Inhibition of metalloproteinase cleavage enhances the cytotoxicity of fas ligand. J Immunol 2003; 170: 677-685.
37. Matsuura JE, Morris AE, Ketchem RR, Braswell EH, Klinke R, Gombotz WR et al. Biophysical characterization of a soluble CD40 ligand (CD154) coiled-coil trimer: evidence of a reversible acid-denatured molten globule. Arch Biochem Biophys 2001; 392: 208-218.
38. Lee JY, Huerta-Yepez S, Vega M, Baritaki S, Spandidos DA, Bonavida B. The NO TRAIL to YES TRAIL in cancer therapy (review). Int J Oncol 2007; 31: 685-691.
39. Callard RE, Armitage RJ, Fanslow WC, Spriggs MK. CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol Today 1993; 14: 559-564.
40. Hayward AR, Levy J, Facchetti F, Notarangelo L, Ochs HD, Etzioni A et al. Cholangiopathy and tumours of the pancreas, liver and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol 1997; 158: 977-983.
41. van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R et al. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA 2002; 99: 5561-5566.
42. French RR, Chan HTC, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T cell help. Nat Med 1999; 5: 548-553.
43. Khanna R, Cooper L, Kienzle N, Moss DJ, Burrows SR, Khanna KK. Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J Immunol 1997; 159: 5782-5785.
44. Davies CC, Mason J, Wakelam MJ, Young LS, Eliopoulos AG. Inhibition of phosphatidylinositol 3-kinase-and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells. J Biol Chem 2004; 279: 1010-1019.
45. Haswell LE, Glennie MJ, Al-Shamkhani A. Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur J Immunol 2001; 31: 3094-3100.
46. Correale P, Aquino A, Giuliani A, Pellegrini M, Micheli L, Cusi MG et al. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoem-bryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int J Cancer 2003; 104: 437-445.
47. Yang S, Haluska FG. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme-and Fas-mediated pathways. J Immunol 2004; 172: 4599-4608.
48. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059.